Social Behavior
Biogen Discontinues Ionis Collaboration on ALS and Angelman Syndrome Treatments Following Early Clinical Results
Biogen, Ionis, ALS, Angelman Syndrome, collaboration, discontinuation, early-stage readouts, clinical trials, treatments, neurological disorders.
Johnson & Johnson Expands into IL-13 and TSLP Market with Strategic Acquisition
Johnson & Johnson, I&I acquisition, IL-13, TSLP, competitive market, strategic expansion, pharmaceutical industry, biologics, inflammatory diseases.
WHO Negotiations Extended for Global Pandemic Agreement
World Health Organization (WHO), pandemic accord, international agreement, global health, deadline, negotiations, public health emergency, disease outbreaks.
FDA Rejects Hepatitis B Vaccine Update Due to Inadequate Documentation and Data
FDA, hepatitis B vaccine, vaccine update, document destruction, insufficient data, rejection
Pioneering Regulatory Compliance in Laboratory Markets: A Strategic Approach
Regulated Labs, Market Strategy, Compliance, Innovation, Leadership
FDA Rejects Dynavax’s Heplisav-B Expansion Due to Data Gaps
FDA, Dynavax, Heplisav-B, data gaps, rejection, expansion, vaccine, hepatitis B
Cytokinetics Unveils Aficamten Data, Gears Up for Market Competition Against Camzyos
Cytokinetics, Aficamten, Camzyos, clinical data, cardiovascular disease, myotonic dystrophy, heart failure, commercial strategy, market competition.
Preliminary CRISPR-Based HIV Treatment Study Shows Limited Success
CRISPR, HIV, gene editing, treatment, study, curative potential, early study, limited success
Innovent Scores Phase 3 Success with Lilly’s Pioneering Obesity Drug for Diabetes Management
Innovent Biologics, Eli Lilly, obesity drug, diabetes management, phase 3 trials, collaboration, metabolic disorders, weight loss, glucose control, next-generation therapy.
Sanofi’s Chief Scientific Officer Frank Nestle Announces Departure
Sanofi, Frank Nestle, Chief Scientific Officer, resignation, pharmaceutical industry, leadership change.